The milestone US-UK deal announced this month on pharmaceuticals, which will mean the NHS pays more for medicines in exchange for a promise of zero tariffs on the industry, still lacks a legal footing beyond top lines contained in two government press releases. Concerns over the basis of the agreement have been heightened by Washington's decision to suspend the 31bn tech prosperity deal, which had been hailed as a generational step-change in our relationship with the US.